Cantor downgrades Supernus on ‘disappointing’ depression study
Cantor Fitzgerald last night downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57. The firm cites ...
Wall Street Journal14d
Supernus Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Seeking Alpha14d
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically ...
Nasdaq15d
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
Investors might want to bet on Supernus Pharmaceuticals (SUPN), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
Yahoo Finance15d
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...
Pharmaceutical Technology15d
Supernus wins FDA approval for Parkinson’s pump on fourth try
Credit: Inside Creative House via Getty Images. Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus ...
Morningstar16d
Supernus Pharmaceuticals Inc SUPN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Finanznachrichten17d
Supernus Pharmaceuticals, Inc.: Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's Disease
Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous ...
Nasdaq17d
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, the First Subcutaneous Apomorphine Infusion Device for Parkinson's Disease in the U.S.
Supernus Pharmaceuticals has announced the FDA approval of ONAPGO, the first subcutaneous apomorphine infusion device specifically designed to treat motor fluctuations in adults with advanced ...
Investing17d
Supernus stock surges on FDA approval
Investing.com -- Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ONAPGO for the treatment of motor fluctuations in adults ...